PHARMACIA & UPJOHN RESCRIPTOR 15.1% REBATE AVAILABLE TO AIDS DRUG ASSISTANCE PROGRAMS; CLINICAL ENDPOINT TRIALS OF COMBINATION WITH PROTEASES PLANNED
Pharmacia & Upjohn is offering a 15.1% rebate of the average manufacturer's price of Rescriptor (delavirdine) to AIDS drug assistance programs that are unable to purchase products at government-discounted rates, the company announced following FDA accelerated approval of the non-nucleoside reverse transcriptase inhibitor on April 4.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth